Breadcrumb

Frederic G. Barr, M.D., Ph.D.

Frederic G. Barr, M.D., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
  • Building 10 - Magnuson CC, Room 3B55
  • Bethesda, MD 20892-1500
  • 301-480-7176
  • barrfg@mail.nih.gov

RESEARCH SUMMARY

Dr. Barr’s research laboratory uses a multidisciplinary approach involving genomics and bioinformatics along with cell culture and animal models to study recurrent chromosomal alterations, such as translocations and amplification, in cancer. His laboratory focuses on rhabdomyosarcoma, a family of myogenic soft tissue cancers usually occurring in children, to investigate the genetic basis, biological consequences, and therapeutic implications of chromosomal alterations in these cancers. In addition, Dr. Barr works closely with clinicians at the National Cancer Institute and in the Children's Oncology Group (the nationwide multi-institutional group conducting treatment trials for pediatric cancer) to investigate the utility of these recurrent chromosomal alterations as biomarkers for diagnosis and management.

Areas of Expertise

1) pediatric cancer 2) sarcoma 3) chromosome translocation 4) gene fusion 5) amplification 6) molecular diagnostics

Publications

Selected Key Publications

Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma

Sun W, Chatterjee B, Shern JF, Patidar R, Song Y, Wang Y, Walker RL, Pawel BR, Linardic CM, Houghton P, Hewitt SM, Edelman DC, Khan J, Meltzer PS, Barr FG.
Int J Cancer. 144(11): 2707-17, 2019. [ Journal Article ]

PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability

Gryder BE, Yohe ME, Chou HC, Zhang X, Marques J, Wachtel M, Schaefer B, Sen N, Song Y, Gualtieri A, Pomella S, Rota R, Cleveland A, Wen X, Sindiri S, Wei JS, Barr FG, Das S, Andresson T, Guha R, Lal-Nag M, Ferrer M, Shern JF, Zhao K, Thomas CJ, Khan J.
Cancer Discov.. 7(8): 884-99, 2017. [ Journal Article ]

Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma.

Sun W, Chatterjee B, Wang Y, Stevenson HS, Edelman DC, Meltzer PS, Barr FG
Modern Pathology. 28: 1214-1224, 2015. [ Journal Article ]

CDK4 amplification reduces sensitivity to CDK4/6 inhibition in fusion-positive rhabdomyosarcoma

Olanich ME, Sun W, Hewitt SM, Abdullaev Z, Pack SD, Barr FG
Clinical Cancer Research. 21: 4947-4959, 2015. [ Journal Article ]

PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma

Pandey PR, Chatterjee B, Olanich ME, Khan J, Miettinen MM, Hewitt SM, Barr FG
Journal of Pathology. 241: 626-637, 2017. [ Journal Article ]

Job Vacancies

Position Degree Required Contact Name Contact Email
Staff Scientist - Cancer biology, genetics Ph.D. or equivalent Frederic G. Barr, MD PhD barrfg@mail.nih.gov

Team

Postdoctoral Fellow (Visiting)
Salah Boudjadi, M.D., Ph.D.
Research Geneticist
Bishwanath Chatterjee, Ph.D.
Postdoctoral Fellow (Visiting)
Thanh Hung Nguyen, Ph.D.
Postdoctoral Fellow (Visiting)
Shabir Zargar, Ph.D.